Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies-Reference-Cited by-同舟云学术

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies

Published:2017-07-27 Issue:1 Volume:19 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Toomey Sinead^ORCID,Eustace Alexander J.,Fay Joanna,Sheehan Katherine M.,Carr Aoife,Milewska Malgorzata,Madden Stephen F.,Teiserskiene Ausra,Kay Elaine W.,O’Donovan Norma,Gallagher William,Grogan Liam,Breathnach Oscar,Walshe Janice,Kelly Catherine,Moulton Brian,Kennedy M. John,Gullo Guiseppe,Hill Arnold D.,Power Colm,Duke Deirdre,Hambly Niamh,Crown John,Hennessy Bryan T.

Funder

Irish Cancer Society

Health Research Board

North East Cancer Research and Education Trust

Science Foundation Ireland

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s13058-017-0883-9.pdf

Reference44 articles.

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–82.

2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–72.